Jennifer R. Eads, MD, discussed radioligand therapy in younger and older patients with NETs, highlighting safety data and ...
Sionna Therapeutics is rated Hold after SION-719 failed its Phase 2a endpoint in cystic fibrosis when combined with Trikafta.
Fat fraction, together with clinical endpoints, may support a potential accelerated approval pathway for forazapadin Protocol ...
Attovia Therapeutics (NASDAQ:ATTO) reported 12-week results from a small phase 1b study of its experimental itch treatment ...
Zydus Therapeutics, a subsidiary of Zydus Lifesciences Limited, has announced encouraging results from its Phase 2b clinical ...
Personalized cancer vaccines are getting closer to market. Merck and Moderna just showed successful manufacturing in a large ...
Rwanda has launched Africa's first clinical trial of a long-acting injectable drug for malaria prevention, marking a potential shift in how the disease is prevented as drug resistance and climate ...
In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how FDA ...
Clinical Trials Arena on MSN
Mondego Bio begins Phase Ia trial of oral MB‑388
The trial is assessing single and multiple ascending doses of MB‑388 in healthy volunteers.
Akeso, Inc. (9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibody ivonescimab in the ...
Immunic (NASDAQ:IMUX) is preparing a Phase 3 trial of its experimental multiple sclerosis drug vidofludimus calcium in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results